Lymphocyte antigen 96 (LY96 or MD2), which is from the toll-like receptor 4 (TLR4) signaling pathway, promotes the development of immunotherapy and targeted therapy of malignancies in tumor occurrence and progression [40]. Here, LY96 is linked to neoplasm.